secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2024-02-13T23:59:59+00:00
Accession:  0001193125-24-032825
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics' CASGEVY receives EU conditional approval for sickle cell disease and beta thalassemia
--------------------------------------------------------------------------------

- European Commission granted conditional marketing authorization for CASGEVY (exa-cel).
- Indicated for patients 12+ with severe sickle cell disease or transfusion-dependent beta thalassemia.
- Eligible when HSCT is appropriate and no HLA-matched related donor is available.
- CMA valid for one year, renewable annually with ongoing data review.
- CASGEVY is a CRISPR/Cas9 gene-edited therapy jointly developed with Vertex.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312524032825/0001193125-24-032825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312524032825/d787773d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-032825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer